BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioMarin Pharmaceutical is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 and an unwillingness to wait for a better entry. The business outlook is improving, but the stock is technically weak and the current setup does not offer a clean buy signal. I would hold off on adding aggressively at this level and wait for a clearer trend improvement.
The short-term technical picture is neutral to bearish. RSI_6 at 48.8 shows no momentum edge. MACD histogram is positive at 0.138 but contracting, which suggests weakening upside momentum. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming the stock is still below a constructive trend structure. Price at 54.08 is just below the pivot at 54.628, with immediate support at 52.724 and resistance at 56.532. The pattern-based forecast also points to a likely -1.24% move next day, though slightly positive over the next week and month.
["Q1 2026 revenue grew 2.83% YoY to $766.2M.", "Management raised full-year 2026 revenue guidance to $3.825B-$3.925B.", "Recent reports suggest the Amicus acquisition could support about 20% revenue growth in 2026.", "Analysts broadly remain positive, with multiple Buy/Overweight/Outperform ratings and several higher price targets.", "VOXZOGO clinical/news flow remains favorable, with positive long-term data and new trial presentations expected."]
["Q1 2026 net income fell 43.17% YoY and EPS dropped 43.16% YoY.", "Gross margin declined to 73.97%, down 6.38% YoY.", "Technical trend is still bearish on moving averages.", "Analyst views are mixed on valuation, with Bernstein cutting its target to $82 while others lifted targets to $116-$120.", "No strong insider, hedge fund, politician, or congress trading support was identified."]
In Q1 2026, BioMarin posted revenue of $766.2M, up 2.83% year over year, showing modest top-line growth. The latest quarter season is Q1 2026. Despite revenue growth, profitability weakened materially: net income fell 43.17% and EPS dropped 43.16% year over year, while gross margin also compressed to 73.97%. That means the company is growing, but earnings quality was softer in the latest quarter.
Analyst sentiment is still positive overall, but increasingly divided on valuation. Canaccord raised its target to $116 and kept a Buy rating after a top-line beat and stronger guidance. Morgan Stanley raised its target to $119 and kept Overweight, while Evercore lifted to $120 and maintained Outperform. Bernstein remains positive but cut its target to $82, citing the EPS miss and softer assumptions. BofA lowered to $85 but kept Buy. Overall, the Wall Street pros view is constructive on the strategic outlook, especially after the Amicus deal, but there is clear disagreement on near-term fair value.
